Real-life cost savings and capacity improvements on implementation of the new BSG post-polypectomy surveillance guideline

• Published in: Clinical medicine (London, England) Vol. 20; no. 1; pp. 116 - 117
• Main Authors: Shandro, Benjamin, Chang, Vincent, Mathur, Jai, O'Neill, Parker, Groves, Christopher, Sadler, Gareth, Poullis, Andrew
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-01-2020; Royal College of Physicians
• Subjects: Clinical Letter; Colonic Polyps; Colonoscopy; Colorectal cancer; Cost control; Cost Savings; Early Detection of Cancer; Endoscopy; Gastroenterology; Guideline Adherence; Humans; Medical screening; Surveillance; Tumors; United Kingdom > UK
• ISSN: 1470-2118; 1473-4893
• DOI: 10.7861/clinmed.2019-0401

Evidence has since emerged demonstrating that patients with LRAs are not at increased risk of colorectal cancer compared to patients with no adenomas detected at colonoscopy, nor to the unexamined general population.2,3 As a result, the new guideline recommends that patients with LRAs be followed up by participation in the national Bowel Cancer Screening Programme (BCSP) when eligible, rather than with colonoscopy surveillance. Implementing the 2019 guideline will lead to an annual cost saving of £75,159 to £87,699, depending on the number of patients<45 years old offered colonoscopy surveillance, and generate capacity for 177 to 207 additional colonoscopies per year. Association of colonoscopy adenoma findings with long-term colorectal cancer incidence.